|
Aug 22
|
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
|
|
Aug 17
|
Cyclo Therapeutics Second Quarter 2024 Earnings: Misses Expectations
|
|
Jul 29
|
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
|
|
Jun 25
|
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
|
|
Jun 14
|
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
|
|
May 30
|
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
|
|
May 16
|
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 10
|
Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
|
|
Mar 18
|
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 14
|
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
|
|
Mar 13
|
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
|
|
Dec 27
|
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
|
|
Dec 18
|
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
|
|
Dec 14
|
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
|
|
Nov 2
|
Several Insiders Invested In Cyclo Therapeutics Flagging Positive News
|
|
Oct 5
|
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
|
|
Aug 15
|
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
|